Clinical Trial Update: Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ensartinib in combination with bevacizumab in ALK-positive non-small cell lung cancer patients with TP53 mutation is active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Ensartinib (Ensartinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING